Drugs / TEZ
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02953314 | Nov 2016 → Sep 2018 | cystic fibrosis | Vertex Pharmaceuticals Incorporated | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TEZ | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02953314 ↗ |
| Route | Oral | “TEZ 50 mg once daily/IVA 75 mg q12h orally for 14 days” NCT02953314 ↗ |